Therapy News and Research

RSS

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

Trimel Pharmaceuticals Corporation announced today that the United States Food and Drug Administration (FDA) has approved Natesto (testosterone), formerly CompleoTRT, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

29 May 2014

Testing for STI co-infections may improve HIV prevention in Africa

To maximize HIV prevention efforts in South Africa and perhaps the broader region, public health officials should consider testing for other sexually transmitted infections when they test for HIV, according to a new paper in the journal Sexually Transmitted Infections.

29 May 2014

MedPage and CollabRx introduce CancerRx to help oncologists, pathologists

MedPage Today, a property of Everyday Health, Inc. and CollabRx, Inc. announced today the introduction of a new physician resource, CancerRx,™ an IOS application designed to help oncologists and pathologists navigate the complex landscape of oncology therapeutic options.

28 May 2014

Physical therapy may not benefit hip osteoarthritis

Researchers have questioned the value of physical therapy for painful hip osteoarthritis in a study published in JAMA.

28 May 2014

Patrys reports positive results from PAT-SM6 clinical trial in patients with multiple myeloma

Patrys Limited, a clinical stage biotechnology company, is pleased to announce the clinical results from a patient treated with PAT-SM6 in combination with other marketed multiple myeloma drugs.

28 May 2014

BioTime receives ISO 13485:2003 certification for development of BioTime HyStem hydrogels

BioTime, Inc. today announced that it has received ISO 13485:2003 certification from BSI (British Standards Institution) for design, development, manufacture, and distribution of BioTime HyStem® hydrogels for cell delivery applications.

28 May 2014

Transgenomic signs license with Dana-Farber to develop multiplexed ICE COLD-PCR technology

Transgenomic, Inc., a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that it has signed a license with the Dana-Farber Cancer Institute for worldwide rights to develop and commercialize multiplexed versions of its ICE COLD-PCRTM technology (MX ICE COLD-PCR).

28 May 2014

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas.

28 May 2014

Researchers recreate human lung in miniature with volume of half cubic centimeter

What medications can be used to treat lung cancer, and how effective are they? Until now, drug companies have had to rely on animal testing to find out. But in the future, a new 3D model lung is set to achieve more precise results and ultimately minimize - or even completely replace - animal testing. From June 23-26, researchers will be presenting their new model at the BIO International Convention in San Diego, California (Germany Pavilion, Booth 4513-03).

28 May 2014

EC approves Takeda's Entyvio for treatment of adults with ulcerative colitis, Crohn’s disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn’s disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.

28 May 2014

New research program to understand and treat debilitating psychiatric disorders

Scientists and physicians at UC San Francisco (UCSF) are leading a $26 million, multi-institutional research program in which they will employ advanced technology to characterize human brain networks and better understand and treat a range of common, debilitating psychiatric disorders, focusing first on anxiety disorders and major depression.

28 May 2014

New fNIRS -FD instrument can identify affected areas of brain

Monitoring the rehabilitation of patients with neurological damage caused by a stroke, has encouraged Mexican scientists to work in the design and manufacture of a functional infrared spectroscopy (fNIRS -FD ) instrument capable of identifying the affected areas of the brain and the sites that were activated while analyzing the oxygen content in blood flow during therapy.

28 May 2014

New understanding of toxicity levels of chemotherapy regimens used for early stage breast cancer

Oncologists now have a new understanding of the toxicity levels of specific chemotherapy regimens used for women with early stage breast cancer, according to research from The University of Texas MD Anderson Cancer Center.

28 May 2014

Study suggests proton therapy may be effective, less toxic treatment option for head and neck cancer

In a small study, researchers from The University of Texas MD Anderson Cancer Center found that 93 percent of head and neck cancer patients treated with multi-field optimization intensity modulated proton therapy (MFO-IMPT) were cancer-free 28 months after treatment.

28 May 2014

Researchers develop active agents that may improve healing of inflammatory illnesses

It is something like the police force of our body: the immune system. It disables intruding pathogens, it dismantles injured tissue and boosts wound healing. In this form of 'self-defense' inflammatory reactions play a decisive role.

27 May 2014

Nationwide Insurance Foundation donates $10M to Nationwide Children's Hospital

Nationwide Children's Hospital today announced that it has received a $10 million gift from the Nationwide Insurance Foundation.

27 May 2014

Inovio announces positive results on DNA-based monoclonal antibody therapy targeting CHIKV

Inovio Pharmaceuticals, Inc. announced today that its novel DNA-based therapeutic monoclonal antibody targeting Chikungunya virus (CHIKV) completely protected mice from a lethal CHIKV challenge.

27 May 2014

Estrogen therapy and venlafaxine treatment effective for hot flashes, night sweats

A new research study from Brigham and Women's Hospital (BWH) that compares low-dose oral estrogen and low-dose non-hormonal venlafaxine hydrochloride extended release (XR) to placebo were both found effective in reducing the number of hot flashes and night sweats reported by menopausal women.

27 May 2014

Study shows positive effects of using hypertonic saline on infants with bronchiolitis

A team of researchers, led by physicians from Children's Hospital Los Angeles, have found that infants with bronchiolitis who were treated with inhaled hypertonic saline in the emergency department (ED) were less likely to require admission to the hospital compared to infants treated with normal saline.

26 May 2014

Dieting may decrease chances for metastases in triple negative breast cancers

Calorie restriction, a kind of dieting in which food intake is decreased by a certain percentage, has been touted as way to help people live longer.

26 May 2014

Therapy News and Research

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

Testing for STI co-infections may improve HIV prevention in Africa

MedPage and CollabRx introduce CancerRx to help oncologists, pathologists

Physical therapy may not benefit hip osteoarthritis

Patrys reports positive results from PAT-SM6 clinical trial in patients with multiple myeloma

BioTime receives ISO 13485:2003 certification for development of BioTime HyStem hydrogels

Transgenomic signs license with Dana-Farber to develop multiplexed ICE COLD-PCR technology

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

Researchers recreate human lung in miniature with volume of half cubic centimeter

EC approves Takeda's Entyvio for treatment of adults with ulcerative colitis, Crohn’s disease

New research program to understand and treat debilitating psychiatric disorders

New fNIRS -FD instrument can identify affected areas of brain

New understanding of toxicity levels of chemotherapy regimens used for early stage breast cancer

Study suggests proton therapy may be effective, less toxic treatment option for head and neck cancer

Researchers develop active agents that may improve healing of inflammatory illnesses

Nationwide Insurance Foundation donates $10M to Nationwide Children's Hospital

Inovio announces positive results on DNA-based monoclonal antibody therapy targeting CHIKV

Estrogen therapy and venlafaxine treatment effective for hot flashes, night sweats

Study shows positive effects of using hypertonic saline on infants with bronchiolitis

Dieting may decrease chances for metastases in triple negative breast cancers

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News